Eli Lilly (NYSE:LLY) First Quarter 2024 Results

Key Financial Results

• Revenue: US$8.77b (up 26% from 1Q 2023).
• Net income: US$2.24b (up 67% from 1Q 2023).
• Profit margin: 26% (up from 19% in 1Q 2023).
• EPS: US$2.49 (up from US$1.49 in 1Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Eli Lilly EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 1.8%. Earnings per share (EPS) exceeded analyst estimates by 1.6%.

Looking ahead, revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 9.3% growth forecast for the Pharmaceuticals industry in the US.

Performance of the American Pharmaceuticals industry.

The company's shares are up 6.1% from a week ago.

Risk Analysis

We should say that we've discovered 2 warning signs for Eli Lilly that you should be aware of before investing here.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.